Use of peptides for the management of Alzheimer's disease: Diagnosis and inhibition

6Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

Abstract

Alzheimer's disease (AD) is a form of dementia and the most common progressive neurodegenerative disease (ND). The targeting of amyloid-beta (Aβ) aggregation is one of the most widely used strategies to manage AD, and efforts are being made globally to develop peptide-based compounds for the early diagnosis and treatment of AD. Here, we briefly discuss the use of peptide-based compounds for the early diagnosis and treatment of AD and the use of peptide-based inhibitors targeting various Aβ aggregation checkpoints. In addition, we briefly discuss recent applications of peptide-based inhibitors against various AD targets including amyloid beta, β-site amyloid precursor protein cleaving enzyme 1 (BACE1), Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), tyrosine phosphatase (TP) and potassium channel KV1.3.

Cite

CITATION STYLE

APA

Baig, M. H., Ahmad, K., Rabbani, G., & Choi, I. (2018, February 7). Use of peptides for the management of Alzheimer’s disease: Diagnosis and inhibition. Frontiers in Aging Neuroscience. Frontiers Media S.A. https://doi.org/10.3389/fnagi.2018.00021

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free